Skip to content

Effect of uricoqing granule on intestinal microflora of gout (spleen deficiency dampness resistance syndrome)

Effect of uricoqing granule on intestinal microflora of gout (spleen deficiency dampness resistance syndrome)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100054235
Enrollment
Unknown
Registered
2021-12-11
Start date
2022-01-01
Completion date
Unknown
Last updated
2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gout

Interventions

Control group:Benbromarone tablets

Sponsors

Yunnan Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Met the diagnostic criteria of primary gout and was in an intermittent period, and the syndrome was spleen deficiency and dampness resistance; 2. Aged 18-65 years; 3. Did not take uric-lowering drugs, did not participate in clinical studies, or stopped eluting drugs for more than 6 months after participating in clinical studies; 4. No gastrointestinal diseases, antibiotics, gastrointestinal motility drugs or probiotics in the past 2 months; 5. Take the test voluntarily and sign the consent form.

Exclusion criteria

Exclusion criteria: 1. Those who are using drugs that affect uric acid metabolism, such as salicylate, furosemide and thiazide diuretics; 2. Those who have been allergic to the drug components used in this study, or are prone to allergic phenomenon; 3. Patients suffering from cardiovascular diseases or serious primary diseases of other organs and systems; 4. Persons suffering from mental diseases; 5. Women in pregnancy or lactation, or those who need to prepare for pregnancy; 6. Overlap with other rheumatic diseases; 7. Those who plan to undergo surgery recently; 8. Persons who are addicted to alcohol, drugs or drugs; 9. Taking antibiotics, probiotics and prebiotics in the last two months; 10. Exclude metabolic diseases (especially those affecting the intestinal flora).

Design outcomes

Primary

MeasureTime frame
Intestinal microflora;SUA;

Countries

China

Contacts

Public ContactPeng Jiangyun

Yunnan Hospital of Traditional Chinese Medicine

pengjiangyun@126.com+86 13099963399

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026